Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

May 30, 2017

PCM-075 Proves Safe as Treatment for Colon, Other Cancer Types, Phase 1 Trial Shows

Trovagene’s PCM-075 therapy for several blood cancers and solid tumors, including colon cancer, proved safe in a Phase 1 clinical trial. The results of the trail conducted by Nerviano ... Read more

May 4, 2017May 4, 2017

RLR Agonists Seen to Promote Immune Response Against Colon Cancer Cells in Early Study

Small molecule compounds known as RLR agonists, being developed by Kineta to treat colon cancer, were seen to kill cancer cells in a mice model of the disease. Those ... Read more

March 29, 2017

Biobank Can Help Colon Cancer Patients Manage Their Disease Better

One way for those with colorectal cancer to become more involved in the management and treatment of their disease is to check out the Penn State Colorectal Diseases Biobank. ... Read more

March 23, 2017March 23, 2017

Gut Bacteria Explains Increased Colon Cancer Risk in African-Americans

The higher intake of animal fat and meat among African-Americans is a potential environmental risk factor for colorectal cancer, as it changes to composition of their gut microbiota, according to ... Read more

February 23, 2017

Inherited Mutations Linked to Colorectal Cancer More Frequent than Believed, Study Finds

The likelihood of having an inherited gene mutation linked to colorectal cancer may be higher than previously believed, according to researchers from the Dana-Farber Cancer Institute. In a study ... Read more

February 21, 2017

Two New Biomarkers May Help Predict Colorectal Cancer Patients’ Response to Therapy

Researchers identified two biomarkers that predict whether patients with colorectal carcinoma will respond well to treatment with Erbitux (cetuximab) or the chemotherapy agent 5FU, according to a new study. ... Read more

February 16, 2017February 16, 2017

Researchers Develop Potential Antibody to Battle Colon, Other Cancers

Researchers have developed a new antibody approach that may help fight a broad range of cancers, including colon cancer, according to a new study. The antibody targets the SIRPα ... Read more

January 10, 2017

MMP9 Protein May Protect Against Inflammation-Derived Colon Cancer

An inflammatory protein called MMP9 may protect against the development of colitis-associated cancer (CAC), a type of colorectal cancer associated with chronic inflammatory diseases, a new study says. The ... Read more

January 3, 2017

Sensor Protein Seen to Protect Against Colon Cancer Development

Results from a new study suggest that a sensor protein called NLRC3 could play an important role in preventing the development of colon cancer. The study, “NLRC3 Is An Inhibitory ... Read more

December 6, 2016December 6, 2016

Diagnostic Agent Detects Colorectal Cancer Response to Therapy in 1 Day in Mice

A preclinical study showed that response of colorectal cancer to treatment can be detected after a single administration using the diagnostic agent TumorVue (99mTc-duramycin), developed by Molecular Targeting Technologies (MTTI). ... Read more

September 27, 2016

Surgical Removal of Primary Tumor in Colon Cancer Patients Doesn’t Improve Survival, Study Finds

Primary tumor resection (surgical removal of the original tumor) does not improve survival compared with chemotherapy in patients with metastatic colon cancer, according to the results of an observational ... Read more